Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CES1 | P23141 | 5/20 | 0.54 |
| ▸ | CES2 | O00748 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8740775 | 1.00 | GSK3B (0.60) | GSK3BTDP1L3MBTL1CES1CES2 | |
| SCHEMBL3362417 | 0.86 | GSK3B (0.57) | GSK3BL3MBTL1LMNAALDH1A1PTPN1 | |
| SCHEMBL9644843 | 0.86 | GSK3B (0.76) | GSK3BTDP1L3MBTL1CES1CES2 | |
| SCHEMBL3703925 | 0.84 | TDP1 (0.56) | GSK3BTDP1L3MBTL1CES1CES2 | |
| SCHEMBL330776 | 0.84 | TDP1 (0.56) | GSK3BTDP1L3MBTL1CES1CES2 | |
| SCHEMBL9157738 | 0.84 | TDP1 (0.56) | GSK3BTDP1L3MBTL1CES1CES2 | |
| SCHEMBL2962521 | 0.82 | GSK3B (0.64) | GSK3BCES1CES2TSHRDAO | |
| SCHEMBL2276402 | 0.82 | CES1 (0.58) | GSK3BTDP1L3MBTL1CES1CES2 | |
| SCHEMBL8488415 | 0.81 | PARP10 (0.58) | GSK3BPGRSMN1; SMN2 | |
| SCHEMBL3361986 | 0.81 | KMO (0.60) | GSK3BTDP1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 955 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036642-A | Methyl pinonate thiazole hydrazone derivative and preparation method and application thereof | 江西农业大学 | 2026-05-15 | — | — | CN | claimed |
| CN-116947609-B | Method for preparing 2, 2-dibromoacetophenone by C-S bond cleavage | 常州大学 | 2025-06-24 | — | — | CN | claimed |
| CN-119977810-A | Preparation process of photoinitiator methyl benzoyl formate | 长沙新宇高分子科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-116769741-B | Fusion protein composition and synthesis method of double-enzyme immobilized PHA microsphere and beta-hydroxy sulfone | 河北牧群生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-116947609-A | Method for preparing 2, 2-dibromoacetophenone by C-S bond cleavage | 常州大学 | 2023-10-27 | — | — | CN | claimed |
| US-20230323293-A1 | EXPANSION CULTURE MEDIUM AND CULTURE METHOD FOR NEURAL CELLS | BEIJING INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE (CN) | 2023-10-12 | — | — | US | claimed |
| CN-116769741-A | Fusion protein composition and synthesis method of double-enzyme immobilized PHA microsphere and beta-hydroxy sulfone | 河北牧群生物科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| EP-4198122-A1 | EXPANSION CULTURE MEDIUM AND CULTURE METHOD FOR NEURAL CELLS | Institute Of Zoology, Chinese Academy Of Sciences (CN) | 2023-06-21 | — | — | EP | claimed |
| CN-115916240-A | Amplification culture medium and culture method of neural cells | 中国科学院动物研究所 | 2023-04-04 | — | — | CN | claimed |
| US-20210290686-A1 | Pathways to Generate Hair Cells | MASSACHUSETTS EYE AND EAR INFIRMARY | 2021-09-23 | — | — | US | claimed |
| WO-2003051295-A2 | NEUTRALIZATION OF STRATUM CORNEUM TO TREAT HYPERKERATOTIC SKIN LESIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-06-26 | — | — | WO | claimed |
| US-20030113352-A1 | Neutralization of stratum corneum to treat hyperkeratotic skin lesions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-06-19 | — | — | US | claimed |
| US-6562606-B1 | Composition for use as tool in the transfer pharmeceutical across epithelial barriers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-13 | — | — | US | claimed |
| US-6190894-B1 | APPLYING INHIBITORS OF BIOSYNTHESIS OR DEGRADATION, DEGRADATION ENZYMES, AND/OR INHIBITORS AND ACTIVATORS OF METABOLIC ENZYMES; FOR TOPICAL ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE SUBSTANCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-20 | — | — | US | claimed |
| WO-1998017253-A1 | METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-30 | — | — | WO | claimed |
| EP-0764017-A4 | METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMA INC (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0764017-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1997-03-26 | — | — | EP | claimed |
| WO-1994021230-A1 | METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| WO-1993019745-A1 | METHOD OF TREATING CLOSTRIDIUM DIFFICILE COLITIS AND CHOLERA | THE UNIVERSITY OF VIRGINIA PATENTS FOUNDATION (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0322262-B1 | BASIC PROTEIN PHOSPHOLIPASE A2 OF AN ELAPIDE SNAKE VENOM, AMINO ACID SEQUENCE THEREOF, DERIVATIVES AND FRAGMENTS THEREOF, PROCESS FOR OBTAINING THEM, THERAPEUTIC COMPOSITIONS AND DIAGNOSTIC AGENTS CONTAINING THEM | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1993-01-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230323293-A1 | EXPANSION CULTURE MEDIUM AND CULTURE METHOD FOR NEURAL CELLS | MYH2, MYH10, MYH14 | GSK3B 46/4885TDP1 3829/4885L3MBTL1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.